scispace - formally typeset
L

Lingyan Zhang

Researcher at University of Southampton

Publications -  8
Citations -  919

Lingyan Zhang is an academic researcher from University of Southampton. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 3, co-authored 4 publications receiving 889 citations.

Papers
More filters
Journal ArticleDOI

A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy.

TL;DR: Although FLT3 abnormalities are uncommon in aCML, SPTBN1-FLT3 is a novel constitutively active tyrosine kinase that appears to responsive to both targeted signal transduction therapy and immunotherapy.
Journal ArticleDOI

Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1.

TL;DR: GDM1, derived from a patient with an atypical MPN (aMPN), is identified as being responsive to imatinib, and it is found that GDM1 expresses CSF1, andCSF1 neutralization partially inhibited proliferation, suggesting the importance of both autocrine and intrinsic mechanisms of CSF 1R activation.
Journal ArticleDOI

Distinct Age-Related Clinical Features and Risk Assessment in Chinese With Chronic Lymphocytic Leukemia

TL;DR: It is demonstrated that CLL patients were characterized by the earlier age at onset in China than in the United States (median age at diagnosis: 63 years old) and the neonatal survival prediction systems were superior to international prognostic index for CLL (CLL-IPI) and Binet stage in assessing the overall survival and progression free survival of C LL patients.
Journal Article

[Application of denaturing high performance liquid chromatography to mutation detection of the c-kit gene in mastocytosis].

TL;DR: It is concluded that denaturing high performance liquid chromatography is a high efficiency and reliable technique for mutation detection of c-kit gene and the detection results would be helpful for the selection of therapy in mastocytosis.